BHL Seeks Manufacturing Rights for Baricitinib Following Licensing Refusal by Incyte and Eli Lilly
shot by IP News Shots / 7:07 pm on 28 June, 2021
Bajaj Healthcare Limited (BHL) has approached the Indian Patent Office seeking compulsory license for Baricitinib as potential treatment option for COVID-19. BHL had first sought a voluntary license for the drug from Incyte Corporation who owns the patent and Eli Lilly and Company, who has the exclusive licensing rights for the drug. Notably, both companies had turned down the voluntary licensing request by BHL.
Read more at The Print